<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00925587</url>
  </required_header>
  <id_info>
    <org_study_id>20060163</org_study_id>
    <secondary_id>2006-003173-27</secondary_id>
    <nct_id>NCT00925587</nct_id>
  </id_info>
  <brief_title>Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease</brief_title>
  <official_title>A Multicenter, Randomised, Double-Blind Study Comparing De Novo Once Monthly and Once Every 2 Week Darbepoetin Alfa Dosing for the Correction of Anemia in Subjects With Chronic Kidney Disease Not Receiving Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether once monthly (QM) dosing of darbepoetin
      alfa is non-inferior to that of once every 2 week (Q2W) dosing of darbepoetin alfa for the
      correction of anemia in patients with Chronic Kidney Disease who are not receiving dialysis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hb Change Between Baseline and the Evaluation Period (Average of Weeks 29-33)</measure>
    <time_frame>Baseline Week 33</time_frame>
    <description>The Adjusted Analysis is the primary analysis and includes treatment group and baseline Hb value as covariates. Non-inferiority is concluded if the lower limit of the 95% confidence interval for the mean difference is above -0.5g/dL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achievement of Both a Hb &gt;= 10.0 g/dL and a &gt;= 1.0 g/dL Increase From Baseline at Any Time Point Following de Novo Darbepoetin Alfa Administration.</measure>
    <time_frame>Baseline to Week 33</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hb at Baseline</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hb at Week 3</measure>
    <time_frame>Week 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hb at Week 5</measure>
    <time_frame>Week 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hb at Week 7</measure>
    <time_frame>Week 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hb at Week 9</measure>
    <time_frame>Week 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hb at Week 11</measure>
    <time_frame>Week 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hb at Week 13</measure>
    <time_frame>Week 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hb at Week 15</measure>
    <time_frame>Week 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hb at Week 17</measure>
    <time_frame>Week 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hb at Week 19</measure>
    <time_frame>Week 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hb at Week 21</measure>
    <time_frame>Week 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hb at Week 23</measure>
    <time_frame>Week 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hb at Week 25</measure>
    <time_frame>Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hb at Week 27</measure>
    <time_frame>Week 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hb at Week 29</measure>
    <time_frame>Week 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hb at Week 31</measure>
    <time_frame>Week 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hb at Week 33</measure>
    <time_frame>Week 33</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Darbepoetin Alfa Dose at Week 1</measure>
    <time_frame>Week 1</time_frame>
    <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Darbepoetin Alfa Dose at Week 3</measure>
    <time_frame>Week 3</time_frame>
    <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Darbepoetin Alfa Dose at Week 5</measure>
    <time_frame>Week 5</time_frame>
    <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Darbepoetin Alfa Dose at Week 7</measure>
    <time_frame>Week 7</time_frame>
    <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Darbepoetin Alfa Dose at Week 9</measure>
    <time_frame>Week 9</time_frame>
    <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Darbepoetin Alfa Dose at Week 11</measure>
    <time_frame>Week 11</time_frame>
    <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Darbepoetin Alfa Dose at Week 13</measure>
    <time_frame>Week 13</time_frame>
    <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Darbepoetin Alfa Dose at Week 15</measure>
    <time_frame>Week 15</time_frame>
    <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Darbepoetin Alfa Dose at Week 17</measure>
    <time_frame>Week 17</time_frame>
    <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Darbepoetin Alfa Dose at Week 19</measure>
    <time_frame>Week 19</time_frame>
    <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Darbepoetin Alfa Dose at Week 21</measure>
    <time_frame>Week 21</time_frame>
    <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Darbepoetin Alfa Dose at Week 23</measure>
    <time_frame>Week 23</time_frame>
    <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Darbepoetin Alfa Dose at Week 25</measure>
    <time_frame>Week 25</time_frame>
    <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Darbepoetin Alfa Dose at Week 27</measure>
    <time_frame>Week 27</time_frame>
    <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Darbepoetin Alfa Dose at Week 29</measure>
    <time_frame>Week 29</time_frame>
    <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Darbepoetin Alfa Dose at Week 31</measure>
    <time_frame>Week 31</time_frame>
    <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Darbepoetin Alfa Dose During the Evaluation Period (Average of Weeks 29-33)</measure>
    <time_frame>Weeks 29-33</time_frame>
    <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Darbepoetin Alfa Dose to Baseline at Week 3</measure>
    <time_frame>Week 3</time_frame>
    <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Darbepoetin Alfa Dose to Baseline at Week 5</measure>
    <time_frame>Week 5</time_frame>
    <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Darbepoetin Alfa Dose to Baseline at Week 7</measure>
    <time_frame>Week 7</time_frame>
    <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Darbepoetin Alfa Dose to Baseline at Week 9</measure>
    <time_frame>Week 9</time_frame>
    <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Darbepoetin Alfa Dose to Baseline at Week 11</measure>
    <time_frame>Week 11</time_frame>
    <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Darbepoetin Alfa Dose to Baseline at Week 13</measure>
    <time_frame>Week 13</time_frame>
    <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Darbepoetin Alfa Dose to Baseline at Week 15</measure>
    <time_frame>Week 15</time_frame>
    <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Darbepoetin Alfa Dose to Baseline at Week 17</measure>
    <time_frame>Week 17</time_frame>
    <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Darbepoetin Alfa Dose to Baseline at Week 19</measure>
    <time_frame>Week 19</time_frame>
    <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Darbepoetin Alfa Dose to Baseline at Week 21</measure>
    <time_frame>Week 21</time_frame>
    <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Darbepoetin Alfa Dose to Baseline at Week 23</measure>
    <time_frame>Week 23</time_frame>
    <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Darbepoetin Alfa Dose to Baseline at Week 25</measure>
    <time_frame>Week 25</time_frame>
    <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Darbepoetin Alfa Dose to Baseline at Week 27</measure>
    <time_frame>Week 27</time_frame>
    <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Darbepoetin Alfa Dose to Baseline at Week 29</measure>
    <time_frame>Week 29</time_frame>
    <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Darbepoetin Alfa Dose to Baseline at Week 31</measure>
    <time_frame>Week 31</time_frame>
    <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose of Darbepoetin Alfa at the First Achievement of a Hb ≥10.0 g/dL and a ≥1.0 g/dL Increase From Baseline (Weeks 1-33)</measure>
    <time_frame>Weeks 1-33</time_frame>
    <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Achievement of a Hb ≥10.0 g/dL and a ≥1.0 g/dL Increase From Baseline (Weeks 1-33)</measure>
    <time_frame>Weeks 1-33</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Darbepoetin Alfa Dose to Baseline at the Evalaution Period (Average of Weeks 29-33)</measure>
    <time_frame>Evaluation Period</time_frame>
    <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">358</enrollment>
  <condition>Anemia</condition>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Q2W</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Q2W administration of darbepoetin alfa.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>QM administration of darbepoetin alfa</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>darbepoetin alfa</intervention_name>
    <description>Drug administered either Q2W or QM using a prefilled syringe. Allowable doses of: 10, 20, 30, 40, 50, 60, 80, 100, 130, 150, 200, 300, 400 or 600 mcg.</description>
    <arm_group_label>Q2W</arm_group_label>
    <arm_group_label>QM</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years of age

          -  Diagnosis of chronic kidney disease with eGFR of 15-59 mL/min/1.73 m2 (MDRD equation)

          -  Two consecutive screening Hb values taken at least 7 days apart must each be &lt;10.0
             g/dL

          -  TSAT ≥ 15%

        Exclusion Criteria:

          -  Upper or lower GI bleeding within 6 months before enrolment

          -  ESA use within 12 weeks before enrolment

          -  Uncontrolled hypertension

          -  Systemic haematologic disorders

          -  Prior history within 12 weeks before enrollment of events including: Acute myocardial
             ischemia, unstable angina, myocardial infarction, hospitalization for congestive heart
             failure, stroke or transient ischaemic attack, limb ischaemia, deep vein thrombosis,
             thromboembolism.

          -  Grand mal seizure within 6 months prior to enrolment

          -  Evidence of, or received chemotherapy or radiation therapy for, a malignancy within 5
             years prior to enrolment.

          -  Red blood cell transfusion within 12 weeks prior to enrolment

          -  Androgen therapy within 8 weeks prior to enrolment

          -  Pregnancy or breast feeding, or inadequate contraception

          -  Currently receiving immunosuppressive therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gosford</city>
        <state>New South Wales</state>
        <zip>2250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Lambton</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cairns</city>
        <state>Queensland</state>
        <zip>4870</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Footscray</city>
        <state>Victoria</state>
        <zip>3011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Reservoir</city>
        <state>Victoria</state>
        <zip>3073</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>LiÃ¨ge</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1709</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <zip>615 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chrudim</city>
        <zip>537 27</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jilemnice</city>
        <zip>514 15</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kladno</city>
        <zip>272 59</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liberec 1</city>
        <zip>460 03</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novy Jicin</city>
        <zip>741 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plzen</city>
        <zip>301 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 10</city>
        <zip>100 34</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 4 - Nusle</city>
        <zip>140 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 4</city>
        <zip>149 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 6</city>
        <zip>160 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 6</city>
        <zip>169 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 8</city>
        <zip>181 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Slavkov u Brna</city>
        <zip>684 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sternberk</city>
        <zip>785 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Usti nad Orlici</city>
        <zip>562 18</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Viborg</city>
        <zip>8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ã…rhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tallinn</city>
        <zip>10617</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tallinn</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Annonay</city>
        <zip>07100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Creil</city>
        <zip>60100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Metz</city>
        <zip>57000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montivilliers</city>
        <zip>76290</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poissy</city>
        <zip>78300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Reims Cedex</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rouen Cedex</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bernkastel-Kues</city>
        <zip>54470</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coesfeld</city>
        <zip>48653</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>DÃ¼sseldorf</city>
        <zip>40210</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22297</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leverkusen</city>
        <zip>51373</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alexandroupoli</city>
        <zip>68100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Larissa</city>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baja</city>
        <zip>6500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1115</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4012</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Esztergom</city>
        <zip>2500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gyor</city>
        <zip>9023</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaposvar</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pecs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szekszard</city>
        <zip>7100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ashkelon</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hadera</city>
        <zip>38100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Albano Laziale RM</city>
        <zip>00041</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ancona</city>
        <zip>60125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cagliari</city>
        <zip>09134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Firenze</city>
        <zip>50141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lecco</city>
        <zip>23900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torino</city>
        <zip>10154</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daugavpils</city>
        <zip>5417</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riga</city>
        <zip>1001</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riga</city>
        <zip>1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riga</city>
        <zip>1038</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valmiera</city>
        <zip>4201</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ventspils</city>
        <zip>3600</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saltillo</city>
        <state>Coahuila</state>
        <zip>25230</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44140</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cuernavaca</city>
        <state>Morelos</state>
        <zip>62448</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Queretaro</city>
        <state>QuerÃ©taro</state>
        <zip>76178</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Luis Potosi</city>
        <state>San Luis PotosÃ-</state>
        <zip>78240</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Choszczno</city>
        <zip>73-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Golub-Dobrzyn</city>
        <zip>87-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koscierzyna</city>
        <zip>83-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koszalin</city>
        <zip>75-581</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Legnica</city>
        <zip>59-220</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-549</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <zip>93-120</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <zip>61-289</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>04-749</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zamosc</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Evora</city>
        <zip>7000-811</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Faro</city>
        <zip>8000-386</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>SetÃºbal</city>
        <zip>2910-446</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucharest</city>
        <zip>010731</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucharest</city>
        <zip>014461</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucharest</city>
        <zip>050098</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iasi</city>
        <zip>700503</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Timisoara</city>
        <zip>300736</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>117036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>123183</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191104</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196247</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>195067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krgujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zemun</city>
        <zip>11080</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bratislava</city>
        <zip>831 03</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Galanta</city>
        <zip>924 22</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Namestovo</city>
        <zip>029 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sala</city>
        <zip>927 19</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trstena</city>
        <zip>028 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zvolen</city>
        <zip>960 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jesenice</city>
        <zip>4270</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novo mesto</city>
        <zip>8000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sempeter pri Gorici</city>
        <zip>5290</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Slovenj Gradec</city>
        <zip>2380</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>JaÃ©n</city>
        <state>AndalucÃ-a</state>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <state>CataluÃ±a</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>CataluÃ±a</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Galdakao</city>
        <state>PaÃ-s Vasco</state>
        <zip>48960</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brighton</city>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coventry</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hull</city>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leicester</city>
        <zip>LE5 4PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shrewsbury</city>
        <zip>SY3 8XQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stevenage</city>
        <zip>SG1 4AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stoke On Trent</city>
        <zip>ST4 7LN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Swansea</city>
        <zip>SA6 6NL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wolverhampton</city>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>South Africa</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2009</study_first_submitted>
  <study_first_submitted_qc>June 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2009</study_first_posted>
  <results_first_submitted>December 5, 2013</results_first_submitted>
  <results_first_submitted_qc>May 15, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 4, 2014</results_first_posted>
  <last_update_submitted>May 15, 2014</last_update_submitted>
  <last_update_submitted_qc>May 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CKD</keyword>
  <keyword>Anemia</keyword>
  <keyword>correction</keyword>
  <keyword>darbepoetin alfa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Darbepoetin Alfa Q2W</title>
          <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
        </group>
        <group group_id="P2">
          <title>Darbepoetin Alfa QM</title>
          <description>Darbepoetin alfa Intravenous Once Monthly</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="178"/>
                <participants group_id="P2" count="180"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="142"/>
                <participants group_id="P2" count="155"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Specified Criteria</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Includes all subjects who received at least one dose of darbepoetin alfa on study. 3 subjects randomized to the Q2W arm failed to administer darbepoetin alfa</population>
      <group_list>
        <group group_id="B1">
          <title>Darbepoetin Alfa Q2W</title>
          <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
        </group>
        <group group_id="B2">
          <title>Darbepoetin Alfa QM</title>
          <description>Darbepoetin alfa Intravenous Once Monthly</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="175"/>
            <count group_id="B2" value="180"/>
            <count group_id="B3" value="355"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.4" spread="14.1"/>
                    <measurement group_id="B2" value="66.3" spread="15.2"/>
                    <measurement group_id="B3" value="67.3" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65-&lt;75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White or Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                    <measurement group_id="B2" value="163"/>
                    <measurement group_id="B3" value="329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Hemoglobin</title>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.13" spread="0.61"/>
                    <measurement group_id="B2" value="9.11" spread="0.70"/>
                    <measurement group_id="B3" value="9.12" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hb Change Between Baseline and the Evaluation Period (Average of Weeks 29-33)</title>
        <description>The Adjusted Analysis is the primary analysis and includes treatment group and baseline Hb value as covariates. Non-inferiority is concluded if the lower limit of the 95% confidence interval for the mean difference is above -0.5g/dL.</description>
        <time_frame>Baseline Week 33</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Hb Change Between Baseline and the Evaluation Period (Average of Weeks 29-33)</title>
          <description>The Adjusted Analysis is the primary analysis and includes treatment group and baseline Hb value as covariates. Non-inferiority is concluded if the lower limit of the 95% confidence interval for the mean difference is above -0.5g/dL.</description>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>g/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.157" lower_limit="1.984" upper_limit="2.330"/>
                    <measurement group_id="O2" value="1.969" lower_limit="1.803" upper_limit="2.135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Power = 90% at sample size calculation</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin -0.5 g/dL</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.188</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.122</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.427</ci_lower_limit>
            <ci_upper_limit>0.052</ci_upper_limit>
            <estimate_desc>Darbepoetin alfa QM - Darbepoetin alfa Q2W</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Achievement of Both a Hb &gt;= 10.0 g/dL and a &gt;= 1.0 g/dL Increase From Baseline at Any Time Point Following de Novo Darbepoetin Alfa Administration.</title>
        <time_frame>Baseline to Week 33</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Achievement of Both a Hb &gt;= 10.0 g/dL and a &gt;= 1.0 g/dL Increase From Baseline at Any Time Point Following de Novo Darbepoetin Alfa Administration.</title>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.9" lower_limit="95.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="98.1" lower_limit="95.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hb at Baseline</title>
        <time_frame>Baseline</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Hb at Baseline</title>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.17" spread="0.05"/>
                    <measurement group_id="O2" value="9.12" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hb at Week 3</title>
        <time_frame>Week 3</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Hb at Week 3</title>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.89" spread="0.08"/>
                    <measurement group_id="O2" value="10.13" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hb at Week 5</title>
        <time_frame>Week 5</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Hb at Week 5</title>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.58" spread="0.08"/>
                    <measurement group_id="O2" value="10.28" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hb at Week 7</title>
        <time_frame>Week 7</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Hb at Week 7</title>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.90" spread="0.09"/>
                    <measurement group_id="O2" value="10.75" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hb at Week 9</title>
        <time_frame>Week 9</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Hb at Week 9</title>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.24" spread="0.10"/>
                    <measurement group_id="O2" value="10.79" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hb at Week 11</title>
        <time_frame>Week 11</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Hb at Week 11</title>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.35" spread="0.10"/>
                    <measurement group_id="O2" value="11.17" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hb at Week 13</title>
        <time_frame>Week 13</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Hb at Week 13</title>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.56" spread="0.10"/>
                    <measurement group_id="O2" value="11.05" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hb at Week 15</title>
        <time_frame>Week 15</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Hb at Week 15</title>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.42" spread="0.11"/>
                    <measurement group_id="O2" value="11.25" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hb at Week 17</title>
        <time_frame>Week 17</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Hb at Week 17</title>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.66" spread="0.10"/>
                    <measurement group_id="O2" value="11.12" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hb at Week 19</title>
        <time_frame>Week 19</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Hb at Week 19</title>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.50" spread="0.12"/>
                    <measurement group_id="O2" value="11.20" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hb at Week 21</title>
        <time_frame>Week 21</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Hb at Week 21</title>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.53" spread="0.10"/>
                    <measurement group_id="O2" value="11.09" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hb at Week 23</title>
        <time_frame>Week 23</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Hb at Week 23</title>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.36" spread="0.09"/>
                    <measurement group_id="O2" value="11.08" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hb at Week 25</title>
        <time_frame>Week 25</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Hb at Week 25</title>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.34" spread="0.10"/>
                    <measurement group_id="O2" value="10.85" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hb at Week 27</title>
        <time_frame>Week 27</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Hb at Week 27</title>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.22" spread="0.09"/>
                    <measurement group_id="O2" value="11.07" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hb at Week 29</title>
        <time_frame>Week 29</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Hb at Week 29</title>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.35" spread="0.10"/>
                    <measurement group_id="O2" value="10.90" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hb at Week 31</title>
        <time_frame>Week 31</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Hb at Week 31</title>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.31" spread="0.09"/>
                    <measurement group_id="O2" value="11.28" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hb at Week 33</title>
        <time_frame>Week 33</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Hb at Week 33</title>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.38" spread="0.10"/>
                    <measurement group_id="O2" value="11.15" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Darbepoetin Alfa Dose at Week 1</title>
        <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
        <time_frame>Week 1</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Darbepoetin Alfa Dose at Week 1</title>
          <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>µg/wk</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.65" spread="0.10" lower_limit="26.59" upper_limit="28.76"/>
                    <measurement group_id="O2" value="27.06" spread="0.10" lower_limit="26.09" upper_limit="28.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Darbepoetin Alfa Dose at Week 3</title>
        <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
        <time_frame>Week 3</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Darbepoetin Alfa Dose at Week 3</title>
          <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>µg/wk</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.80" spread="0.10" lower_limit="24.64" upper_limit="27.00"/>
                    <measurement group_id="O2" value="27.06" spread="0.10" lower_limit="26.09" upper_limit="28.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Darbepoetin Alfa Dose at Week 5</title>
        <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
        <time_frame>Week 5</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Darbepoetin Alfa Dose at Week 5</title>
          <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>µg/wk</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.40" spread="0.10" lower_limit="22.70" upper_limit="26.23"/>
                    <measurement group_id="O2" value="24.52" spread="0.10" lower_limit="22.70" upper_limit="26.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Darbepoetin Alfa Dose at Week 7</title>
        <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
        <time_frame>Week 7</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Darbepoetin Alfa Dose at Week 7</title>
          <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>µg/wk</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.42" spread="0.10" lower_limit="21.42" upper_limit="25.61"/>
                    <measurement group_id="O2" value="24.52" spread="0.10" lower_limit="22.70" upper_limit="26.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Darbepoetin Alfa Dose at Week 9</title>
        <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
        <time_frame>Week 9</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Darbepoetin Alfa Dose at Week 9</title>
          <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>µg/wk</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.01" spread="0.10" lower_limit="17.36" upper_limit="23.07"/>
                    <measurement group_id="O2" value="20.59" spread="0.10" lower_limit="17.89" upper_limit="23.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Darbepoetin Alfa Dose at Week 11</title>
        <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
        <time_frame>Week 11</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Darbepoetin Alfa Dose at Week 11</title>
          <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>µg/wk</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.99" spread="0.10" lower_limit="16.22" upper_limit="22.24"/>
                    <measurement group_id="O2" value="20.50" spread="0.10" lower_limit="17.83" upper_limit="23.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Darbepoetin Alfa Dose at Week 13</title>
        <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
        <time_frame>Week 13</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Darbepoetin Alfa Dose at Week 13</title>
          <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>µg/wk</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.67" spread="0.10" lower_limit="11.97" upper_limit="17.98"/>
                    <measurement group_id="O2" value="19.52" spread="0.10" lower_limit="16.79" upper_limit="22.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Darbepoetin Alfa Dose at Week 15</title>
        <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
        <time_frame>Week 15</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Darbepoetin Alfa Dose at Week 15</title>
          <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>µg/wk</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.19" spread="0.10" lower_limit="11.52" upper_limit="17.47"/>
                    <measurement group_id="O2" value="19.15" spread="0.10" lower_limit="16.42" upper_limit="22.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Darbepoetin Alfa Dose at Week 17</title>
        <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
        <time_frame>Week 17</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Darbepoetin Alfa Dose at Week 17</title>
          <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>µg/wk</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.71" spread="0.10" lower_limit="10.15" upper_limit="15.92"/>
                    <measurement group_id="O2" value="19.94" spread="0.10" lower_limit="17.28" upper_limit="23.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Darbepoetin Alfa Dose at Week 19</title>
        <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
        <time_frame>Week 19</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Darbepoetin Alfa Dose at Week 19</title>
          <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>µg/wk</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.52" spread="0.10" lower_limit="11.97" upper_limit="17.61"/>
                    <measurement group_id="O2" value="19.94" spread="0.10" lower_limit="17.28" upper_limit="23.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Darbepoetin Alfa Dose at Week 21</title>
        <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
        <time_frame>Week 21</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Darbepoetin Alfa Dose at Week 21</title>
          <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>µg/wk</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.42" spread="0.10" lower_limit="12.96" upper_limit="18.36"/>
                    <measurement group_id="O2" value="21.59" spread="0.10" lower_limit="19.20" upper_limit="24.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Darbepoetin Alfa Dose at Week 23</title>
        <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
        <time_frame>Week 23</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Darbepoetin Alfa Dose at Week 23</title>
          <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>µg/wk</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.73" spread="0.10" lower_limit="12.35" upper_limit="17.57"/>
                    <measurement group_id="O2" value="19.98" spread="0.10" lower_limit="17.39" upper_limit="22.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Darbepoetin Alfa Dose at Week 25</title>
        <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
        <time_frame>Week 25</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Darbepoetin Alfa Dose at Week 25</title>
          <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>µg/wk</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.55" spread="0.10" lower_limit="12.16" upper_limit="17.41"/>
                    <measurement group_id="O2" value="20.70" spread="0.10" lower_limit="18.10" upper_limit="23.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Darbepoetin Alfa Dose at Week 27</title>
        <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
        <time_frame>Week 27</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Darbepoetin Alfa Dose at Week 27</title>
          <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>µg/wk</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.07" spread="0.10" lower_limit="13.69" upper_limit="18.85"/>
                    <measurement group_id="O2" value="20.79" spread="0.10" lower_limit="18.18" upper_limit="23.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Darbepoetin Alfa Dose at Week 29</title>
        <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
        <time_frame>Week 29</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Darbepoetin Alfa Dose at Week 29</title>
          <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>µg/wk</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.06" spread="0.10" lower_limit="12.75" upper_limit="17.78"/>
                    <measurement group_id="O2" value="20.57" spread="0.10" lower_limit="17.74" upper_limit="23.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Darbepoetin Alfa Dose at Week 31</title>
        <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
        <time_frame>Week 31</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Darbepoetin Alfa Dose at Week 31</title>
          <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>µg/wk</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.48" spread="0.10" lower_limit="12.20" upper_limit="17.19"/>
                    <measurement group_id="O2" value="19.39" spread="0.10" lower_limit="16.51" upper_limit="22.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Darbepoetin Alfa Dose During the Evaluation Period (Average of Weeks 29-33)</title>
        <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
        <time_frame>Weeks 29-33</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Darbepoetin Alfa Dose During the Evaluation Period (Average of Weeks 29-33)</title>
          <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>µg/wk</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.21" spread="0.10" lower_limit="12.99" upper_limit="17.81"/>
                    <measurement group_id="O2" value="19.68" spread="0.10" lower_limit="16.84" upper_limit="23.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of Darbepoetin Alfa Dose to Baseline at Week 3</title>
        <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
        <time_frame>Week 3</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Darbepoetin Alfa Dose to Baseline at Week 3</title>
          <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.931" spread="0.10" lower_limit="0.914" upper_limit="0.947"/>
                    <measurement group_id="O2" value="1.000" spread="0.10" lower_limit="1.000" upper_limit="1.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of Darbepoetin Alfa Dose to Baseline at Week 5</title>
        <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
        <time_frame>Week 5</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Darbepoetin Alfa Dose to Baseline at Week 5</title>
          <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.882" spread="0.10" lower_limit="0.832" upper_limit="0.936"/>
                    <measurement group_id="O2" value="0.907" spread="0.10" lower_limit="0.845" upper_limit="0.974"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of Darbepoetin Alfa Dose to Baseline at Week 7</title>
        <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
        <time_frame>Week 7</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Darbepoetin Alfa Dose to Baseline at Week 7</title>
          <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.845" spread="0.10" lower_limit="0.782" upper_limit="0.914"/>
                    <measurement group_id="O2" value="0.907" spread="0.10" lower_limit="0.845" upper_limit="0.974"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of Darbepoetin Alfa Dose to Baseline at Week 9</title>
        <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
        <time_frame>Week 9</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Darbepoetin Alfa Dose to Baseline at Week 9</title>
          <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.724" spread="0.10" lower_limit="0.631" upper_limit="0.832"/>
                    <measurement group_id="O2" value="0.761" spread="0.10" lower_limit="0.662" upper_limit="0.875"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of Darbepoetin Alfa Dose to Baseline at Week 11</title>
        <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
        <time_frame>Week 11</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Darbepoetin Alfa Dose to Baseline at Week 11</title>
          <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.684" spread="0.10" lower_limit="0.588" upper_limit="0.797"/>
                    <measurement group_id="O2" value="0.758" spread="0.10" lower_limit="0.659" upper_limit="0.871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of Darbepoetin Alfa Dose to Baseline at Week 13</title>
        <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
        <time_frame>Week 13</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Darbepoetin Alfa Dose to Baseline at Week 13</title>
          <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.531" spread="0.10" lower_limit="0.435" upper_limit="0.647"/>
                    <measurement group_id="O2" value="0.719" spread="0.10" lower_limit="0.620" upper_limit="0.835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of Darbepoetin Alfa Dose to Baseline at Week 15</title>
        <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
        <time_frame>Week 15</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Darbepoetin Alfa Dose to Baseline at Week 15</title>
          <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.512" spread="0.10" lower_limit="0.417" upper_limit="0.628"/>
                    <measurement group_id="O2" value="0.707" spread="0.10" lower_limit="0.608" upper_limit="0.823"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of Darbepoetin Alfa Dose to Baseline at Week 17</title>
        <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
        <time_frame>Week 17</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Darbepoetin Alfa Dose to Baseline at Week 17</title>
          <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.459" spread="0.10" lower_limit="0.368" upper_limit="0.572"/>
                    <measurement group_id="O2" value="0.737" spread="0.10" lower_limit="0.641" upper_limit="0.847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of Darbepoetin Alfa Dose to Baseline at Week 19</title>
        <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
        <time_frame>Week 19</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Darbepoetin Alfa Dose to Baseline at Week 19</title>
          <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.525" spread="0.10" lower_limit="0.435" upper_limit="0.633"/>
                    <measurement group_id="O2" value="0.737" spread="0.10" lower_limit="0.641" upper_limit="0.846"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of Darbepoetin Alfa Dose to Baseline at Week 21</title>
        <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
        <time_frame>Week 21</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Darbepoetin Alfa Dose to Baseline at Week 21</title>
          <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.556" spread="0.10" lower_limit="0.471" upper_limit="0.656"/>
                    <measurement group_id="O2" value="0.797" spread="0.10" lower_limit="0.713" upper_limit="0.891"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of Darbepoetin Alfa Dose to Baseline at Week 23</title>
        <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
        <time_frame>Week 23</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Darbepoetin Alfa Dose to Baseline at Week 23</title>
          <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.533" spread="0.10" lower_limit="0.450" upper_limit="0.632"/>
                    <measurement group_id="O2" value="0.738" spread="0.10" lower_limit="0.646" upper_limit="0.844"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of Darbepoetin Alfa Dose to Baseline at Week 25</title>
        <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
        <time_frame>Week 25</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Darbepoetin Alfa Dose to Baseline at Week 25</title>
          <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.526" spread="0.10" lower_limit="0.443" upper_limit="0.625"/>
                    <measurement group_id="O2" value="0.764" spread="0.10" lower_limit="0.671" upper_limit="0.869"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of Darbepoetin Alfa Dose to Baseline at Week 27</title>
        <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
        <time_frame>Week 27</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Darbepoetin Alfa Dose to Baseline at Week 27</title>
          <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.581" spread="0.10" lower_limit="0.499" upper_limit="0.677"/>
                    <measurement group_id="O2" value="0.768" spread="0.10" lower_limit="0.675" upper_limit="0.875"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of Darbepoetin Alfa Dose to Baseline at Week 29</title>
        <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
        <time_frame>Week 29</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Darbepoetin Alfa Dose to Baseline at Week 29</title>
          <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.544" spread="0.10" lower_limit="0.462" upper_limit="0.640"/>
                    <measurement group_id="O2" value="0.762" spread="0.10" lower_limit="0.661" upper_limit="0.880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of Darbepoetin Alfa Dose to Baseline at Week 31</title>
        <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
        <time_frame>Week 31</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Darbepoetin Alfa Dose to Baseline at Week 31</title>
          <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.525" spread="0.10" lower_limit="0.443" upper_limit="0.622"/>
                    <measurement group_id="O2" value="0.717" spread="0.10" lower_limit="0.613" upper_limit="0.839"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose of Darbepoetin Alfa at the First Achievement of a Hb ≥10.0 g/dL and a ≥1.0 g/dL Increase From Baseline (Weeks 1-33)</title>
        <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
        <time_frame>Weeks 1-33</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Dose of Darbepoetin Alfa at the First Achievement of a Hb ≥10.0 g/dL and a ≥1.0 g/dL Increase From Baseline (Weeks 1-33)</title>
          <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>µg/wk</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.95" spread="0.10" lower_limit="24.43" upper_limit="27.56"/>
                    <measurement group_id="O2" value="29.65" spread="0.10" lower_limit="27.89" upper_limit="31.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Achievement of a Hb ≥10.0 g/dL and a ≥1.0 g/dL Increase From Baseline (Weeks 1-33)</title>
        <time_frame>Weeks 1-33</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Achievement of a Hb ≥10.0 g/dL and a ≥1.0 g/dL Increase From Baseline (Weeks 1-33)</title>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="3.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="5.0" lower_limit="3.0" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of Darbepoetin Alfa Dose to Baseline at the Evalaution Period (Average of Weeks 29-33)</title>
        <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
        <time_frame>Evaluation Period</time_frame>
        <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa Q2W</title>
            <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Darbepoetin Alfa QM</title>
            <description>Darbepoetin alfa Intravenous Once Monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Darbepoetin Alfa Dose to Baseline at the Evalaution Period (Average of Weeks 29-33)</title>
          <description>Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</description>
          <population>Primary Analysis Set: All subjects receiving at least one dose of darbepoetin alfa in the treatment group to which they were randomized and with at least one evaluable (not within 90 days after an RBC transfusion) Hb measurement during the evaluation period (Weeks 29-33)</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.550" spread="0.10" lower_limit="0.471" upper_limit="0.643"/>
                    <measurement group_id="O2" value="0.728" spread="0.10" lower_limit="0.625" upper_limit="0.849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>33 weeks</time_frame>
      <desc>The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.
Summary of Adverse Events includes only those subjects who received at least one dose of investigational product.</desc>
      <group_list>
        <group group_id="E1">
          <title>Darbepoetin Alfa Q2W</title>
          <description>Darbepoetin alfa Intravenous Once Every 2 Weeks</description>
        </group>
        <group group_id="E2">
          <title>Darbepoetin Alfa QM</title>
          <description>Darbepoetin alfa Intravenous Once Monthly</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Acute abdomen</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Alcoholic pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Diaphragmatic hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anti-neutrophil cytoplasmic antibody positive vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Parainfluenzae virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Skull fractured base</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>General physical condition abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Vascular encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Oedema genital</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Scrotal swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

